Literature DB >> 31800958

Protease activity in single-chain prekallikrein.

Ivan Ivanov1, Ingrid M Verhamme1, Mao-Fu Sun1, Bassem Mohammed1, Qiufang Cheng1, Anton Matafonov1, S Kent Dickeson1, Kusumam Joseph2, Allen P Kaplan3, David Gailani1.   

Abstract

Prekallikrein (PK) is the precursor of the trypsin-like plasma protease kallikrein (PKa), which cleaves kininogens to release bradykinin and converts the protease precursor factor XII (FXII) to the enzyme FXIIa. PK and FXII undergo reciprocal conversion to their active forms (PKa and FXIIa) by a process that is accelerated by a variety of biological and artificial surfaces. The surface-mediated process is referred to as contact activation. Previously, we showed that FXII expresses a low level of proteolytic activity (independently of FXIIa) that may initiate reciprocal activation with PK. The current study was undertaken to determine whether PK expresses similar activity. Recombinant PK that cannot be converted to PKa was prepared by replacing Arg371 with alanine at the activation cleavage site (PK-R371A, or single-chain PK). Despite being constrained to the single-chain precursor form, PK-R371A cleaves high-molecular-weight kininogen (HK) to release bradykinin with a catalytic efficiency ∼1500-fold lower than that of kallikrein cleavage of HK. In the presence of a surface, PK-R371A converts FXII to FXIIa with a specific activity ∼4 orders of magnitude lower than for PKa cleavage of FXII. These results support the notion that activity intrinsic to PK and FXII can initiate reciprocal activation of FXII and PK in solution or on a surface. The findings are consistent with the hypothesis that the putative zymogens of many trypsin-like proteases are actually active proteases, explaining their capacity to undergo processes such as autoactivation and to initiate enzyme cascades.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31800958      PMCID: PMC7033373          DOI: 10.1182/blood.2019002224

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  61 in total

Review 1.  Activation of the hemostatic system during cardiopulmonary bypass.

Authors:  Roman M Sniecinski; Wayne L Chandler
Journal:  Anesth Analg       Date:  2011-10-14       Impact factor: 5.108

Review 2.  Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology.

Authors:  Irma M Sainz; Robin A Pixley; Robert W Colman
Journal:  Thromb Haemost       Date:  2007-07       Impact factor: 5.249

3.  Location of the disulfide bonds in human plasma prekallikrein: the presence of four novel apple domains in the amino-terminal portion of the molecule.

Authors:  B A McMullen; K Fujikawa; E W Davie
Journal:  Biochemistry       Date:  1991-02-26       Impact factor: 3.162

4.  Toward a better understanding of factor XI activation.

Authors:  David Gailani; Jonas Emsley
Journal:  J Thromb Haemost       Date:  2019-12       Impact factor: 5.824

Review 5.  Hereditary angioedema: the plasma contact system out of control.

Authors:  S De Maat; Z L M Hofman; C Maas
Journal:  J Thromb Haemost       Date:  2018-07-17       Impact factor: 5.824

6.  Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.

Authors:  Kusumam Joseph; Baby G Tholanikunnel; Allen P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

Review 7.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

8.  Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats.

Authors:  D W Chung; K Fujikawa; B A McMullen; E W Davie
Journal:  Biochemistry       Date:  1986-05-06       Impact factor: 3.162

9.  Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman Factor).

Authors:  G Tans; J Rosing; J H Griffin
Journal:  J Biol Chem       Date:  1983-07-10       Impact factor: 5.157

Review 10.  Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.

Authors:  Benjamin Tillman; David Gailani
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

View more
  3 in total

1.  Kallikrein augments the anticoagulant function of the protein C system in thrombin generation.

Authors:  Jun Wan; Nadira Vadaq; Joke Konings; Martin Jaeger; Vinod Kumar; Bas de Laat; Leo Joosten; Mihai G Netea; Andre J van der Ven; Philip G de Groot; Quirijn de Mast; Mark Roest
Journal:  J Thromb Haemost       Date:  2021-09-28       Impact factor: 16.036

Review 2.  Proteolytic activity of contact factor zymogens.

Authors:  Aleksandr Shamanaev; Jonas Emsley; David Gailani
Journal:  J Thromb Haemost       Date:  2020-12-07       Impact factor: 5.824

3.  Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI.

Authors:  Katherine J Kearney; Juliet Butler; Olga M Posada; Clare Wilson; Samantha Heal; Majid Ali; Lewis Hardy; Josefin Ahnström; David Gailani; Richard Foster; Emma Hethershaw; Colin Longstaff; Helen Philippou
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.